7,556.00

-18.50

-0.24%

51,861.00

-272.00

-0.52%

28,099.25

-28.25

-0.10%

Russell 2000 Futures

2,810.80

-7.00

-0.25%

4.8940

-0.0350

-0.71%

21.15

+1.73

+8.91%

3,922.50

-47.10

-1.19%

76,406.78

-1,581.30

-2.03%

Crude Oil Dec 26

98.07

+1.61

+1.67%

US Private Equity

10,836.30

-14.33

-0.13%

NasdaqGM - Delayed Quote USD

YD Bio Limited (YDESW)

0.5490 -0.1109 (-16.81%)

At close: November 2 at 4:00:00 PM EST

Loading Chart for YDESW

Chart Range Bar

Interval:

In partnership with ChartIQ

YD Bio Limited Reports Unaudited Financial Results for the Six Months Ended June 30, 2026

YD Bio Limited Reports Unaudited Financial Results for the Six Months Ended June 30, 2026

YD Bio Announces Peer-Reviewed Publication in Nutrients, Co-Authored with Physicians from the Taiwan Chronic Disease Healthcare Association and the Future Health Institute

YD Bio Announces Peer-Reviewed Publication in Nutrients, Co-Authored with Physicians from the Taiwan Chronic Disease Healthcare Association and the Future Health Institute

YD Bio Launches a Physician-Partnership Initiative in Taiwan with the Announcement of Two Nutraceutical Products in Collaboration with the Taiwan Chronic Disease Healthcare Association and the Future Health Institute

YD Bio Launches a Physician-Partnership Initiative in Taiwan with the Announcement of Two Nutraceutical Products in Collaboration with the Taiwan Chronic Disease Healthcare Association and the Future Health Institute

YD Bio Highlights Peer-Reviewed Publication on New Computational Framework for Keratoconus Research

YD Bio Highlights Peer-Reviewed Publication on New Computational Framework for Keratoconus Research

YD Bio Launches Cross-Border Cancer Testing Pilot with Numia Health to Evaluate Expanded Access to Molecular Diagnostics in Canada

YD Bio Launches Cross-Border Cancer Testing Pilot with Numia Health to Evaluate Expanded Access to Molecular Diagnostics in Canada

YD Bio and EG BioMed Conclude Successful Exhibition at BIO Asia-Taiwan 2026, Highlighting Innovations in Ophthalmology, Oncology Diagnostics, and Clinical Services

YD Bio and EG BioMed Conclude Successful Exhibition at BIO Asia-Taiwan 2026, Highlighting Innovations in Ophthalmology, Oncology Diagnostics, and Clinical Services

YD Bio Expands U.S. Laboratory Footprint to 46 States, Strengthening DNA-Methylation Early Cancer Detection Operations

YD Bio Expands U.S. Laboratory Footprint to 46 States, Strengthening DNA-Methylation Early Cancer Detection Operations

YD Bio Limited Reports Full Year 2025 Financial Results

YD Bio Limited Reports Full Year 2025 Financial Results

YD Bio and EG BioMed Partner with JoiiUp to Launch AI-Driven Cancer Risk Assessment for Corporate Wellness Programs

YD Bio and EG BioMed Partner with JoiiUp to Launch AI-Driven Cancer Risk Assessment for Corporate Wellness Programs

YD Bio and EG BioMed Launch AI-Based 10-Cancer Risk Factor Assessment

YD Bio and EG BioMed Launch AI-Based 10-Cancer Risk Factor Assessment

YD Bio and EG BioMed Jointly Launch Nationwide Telehealth Platform to Accelerate Commercialization of Cancer Detection and Decentralized Clinical Services Across the United States

YD Bio and EG BioMed Jointly Launch Nationwide Telehealth Platform to Accelerate Commercialization of Cancer Detection and Decentralized Clinical Services Across the United States

Mobilize your Website

View Site in Mobile | Classic

Share by: